Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02991807
Recruitment Status : Completed
First Posted : December 14, 2016
Last Update Posted : February 8, 2022
National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Office of Rare Diseases (ORD)
National Center for Advancing Translational Science (NCATS)
Novartis Pharmaceuticals
PTEN Research
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Mustafa Sahin, Boston Children's Hospital

Results Submitted - Quality Control (QC) Review Has Not Concluded
Results information for an applicable clinical trial (ACT) is posted within 30 days of submission even if the submission has not completed the Results Quality Control (QC) review process. Results information is submitted to by the sponsor or investigator, and National Library of Medicine (NLM) staff assess for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

All versions of ACT results information submissions that have not completed the QC review process are posted on (since January 2020). After the QC review process is completed, the results information is posted without QC review comments and previous versions are archived.

Recruitment Status : Completed
Actual Primary Completion Date : February 18, 2021
Actual Study Completion Date : December 22, 2021
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 May 6, 2022
June 2, 2022 Submission with QC Comments